3rd International Conference on Chemo and BioInformatics, Kragujevac, September 25-26, 2025. (pp. 58-60)
АУТОР(И) / AUTHOR(S): Oguzhan Akgun
Download Full Pdf 
DOI: 10.46793/ICCBIKG25.058A
САЖЕТАК / ABSTRACT:
Translational approaches in cancer research aim to accelerate the transfer of fundamental scientific discoveries into clinical applications, providing a multidisciplinary framework for innovative diagnostics, therapeutic strategies, and preventive interventions. The integration of multi-omics data—encompassing genomic, transcriptomic, proteomic, metabolomic, and epigenomic profiles—offers a robust platform for unraveling the complex molecular landscape of tumors and identifying clinically relevant biomarkers. Patient-derived organoids and cell line models further enhance the predictive power of these analyses by enabling accurate modeling of tumor initiation, progression, and treatment response.
Methodologically, mutation, methylation, RNA, and miRNA sequencing data were analyzed using R-based packages including Maftools, DESeq2, ELMER, MultiAssayExperiment, mirNet, and WGCNA, with network visualizations performed in Cytoscape. Over-representation analyses on highly correlated genes/miRNAs from PCA across clinical parameters facilitated the identification of the most statistically discriminative biomarkers.
Overall, the validation of multi-omic findings using organoid and cell models significantly enhanced the reliability and efficiency of biomarker research. This integrated approach enables rapid identification and functional validation of predictive and prognostic biomarkers, supporting the development of personalized therapeutic strategies in lung cancer. By linking molecular-level insights to clinically actionable targets, this workflow strengthens translational research and informs precision oncology decision-making.
КЉУЧНЕ РЕЧИ / KEYWORDS:
Multi-omics, organoids, biomarkers, translational research
ПРОЈЕКАТ / ACKNOWLEDGEMENT:
We thank Bursa Uludag Molecular Cancer Research Laboratory (BUMKAL) for their valuable support and contributions to this study.
ЛИТЕРАТУРА / REFERENCES:
- M. C. Casotti et al., Translational Bioinformatics Applied to the Study of Complex Diseases, Genes (Basel), vol. 14, no. 2, p. 419, Feb. 2023, doi: 10.3390/genes14020419.
- D. Ha et al., Development of bioinformatics and multi-omics analyses in organoids, BMB Rep, vol. 56, no. 1, pp. 43–48, Jan. 2023, doi: 10.5483/BMBRep.2022-0155.
- S. Chitrangi, P. Vaity, A. Jamdar, and S. Bhatt, Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making, BMC Cancer, vol. 23, no. 1, p. 689, Jul. 2023, doi: 10.1186/s12885-023-11078-9.
- L. Tong et al., Patient-derived organoids in precision cancer medicine, Med, vol. 5, no. 11, pp. 1351–1377, Nov. 2024, doi: 10.1016/j.medj.2024.08.010.
- V. Raufaste-Cazavieille, R. Santiago, and A. Droit, Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology, Front Mol Biosci, vol. 9, Oct. 2022, doi: 10.3389/fmolb.2022.962743.
- D. Ha et al., Development of bioinformatics and multi-omics analyses in organoids, BMB Rep, vol. 56, no. 1, pp. 43–48, Jan. 2023, doi: 10.5483/BMBRep.2022-0155.